Indoramin in the treatment of hypertension. A mini-review and update

The origins, preclinical development and clinical pharmacology of a new antihypertensive agent, indoramin (Baratol; Wyeth), are briefly reviewed. Indoramin is a competitive postsynaptic alpha-adrenoceptor antagonist with a myocardial membrane-stabilizing component of action. These features are believed to be responsible for its antihypertensive efficacy. They may also explain the absence of problems common to older alpha-blockers such as reflex tachycardia and postural hypotension. Clinical evaluation of a new agent such as indoramin in the management of hypertension is discussed in terms of efficacy, dosage regimen, tolerance, adverse effects, interactions, withdrawal syndrome, and long-term influence on the complications of high blood pressure.